Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD
- PMID: 9833620
Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT--25 years experiences of KRI-TRD
Abstract
A retrospective and comparative study of high-risk gestational trophoblastic tumor (GTT) treated with different chemoregimen from 1971 to 1995 was performed and to find most effective chemotherapy regimen and independent risk factors. Three hundred seven patients in scoring over 8 points in WHO classification were categorized into high-risk group among 802 GTT cases received chemotherapy in the 2,418 GTD patients registered at KRI-TRD (Korean Research Institute for Gestational Trophoblastic Disease), Catholic University Medical College in Korea. Study groups of multiagent combination chemotherapy in 227 patients of the high-risk GTT were divided such as 49 cases of combination chemotherapy with MTX + folinic acid and Act-D, 40 cases of MAC regimen, 42 cases of CHAMOCA regimen, and 96 cases of EMA/CO. Initial tumor response according to hCG titer decrease was found in good response (log fall) 69.8%, of EMA /CO regimen group. On the other hand, good response was shown in only 24.5% of MTX + ACT-D, 32.5% of MAC regimen, and 52.4%, of CHAMOCA regimen respectively. Remission rate of EMA/CO regimen was 90.6% (87/96) and courses of chemotherapy until remission was 8.5+/-2.2. However, remission rate of other regimens of MTX + Act-D, MAC, and CHAMOCA were 63.3%, (31/49) 67.5% (27/40) and 76.2% (32/45) respectively, with 10.0+/-4.0, 10.7+/-4.3, 9.1+/-3.9 chemotherapy courses respectively until remission. Therefore, EMA/CO regimen groups were found to have low drug toxicity, early remission and a low failure rate. In the study of independent risk factors in the 165 cases of high-risk gestational trophoblastic tumor patients received EMA/CO regimen, stepwise Coxs proportional hazard's regression of prognostic factors using multivariate analysis revealed tumor age, number of metastatic organs, metastatic site and inadequate previous chemotherapy. According to the performance of fitted logistic regression model, the prediction rate of death and survival was 80.5%.
Conclusions: The most effective chemotherapy to high-risk GTT was EMA/CO regimen than other regimens. The following factors showed poor prognosis; 1) Tumor age is over 12 month, 2) more than 2 organs had metastatic lesion, 3) inadequate previous therapy that includes unplanned operation and inadequate previous chemotherapy.
Similar articles
-
Effects of multiagent chemotherapy and independent risk factors in the treatment of high-risk GTT -25 years experiences of KRI-TRD.Int J Gynaecol Obstet. 1998 Apr;60 Suppl 1:S85-S96. doi: 10.1016/S0020-7292(98)80010-6. Int J Gynaecol Obstet. 1998. PMID: 29645247
-
Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors.J Clin Oncol. 2000 Feb;18(4):854-9. doi: 10.1200/JCO.2000.18.4.854. J Clin Oncol. 2000. PMID: 10673528
-
EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT).Gynecol Oncol. 1988 Nov;31(3):439-44. doi: 10.1016/s0090-8258(88)80029-5. Gynecol Oncol. 1988. PMID: 2846414
-
Combination chemotherapy for high-risk gestational trophoblastic tumour.Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005196. doi: 10.1002/14651858.CD005196.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2009 Apr 15;(2):CD005196. doi: 10.1002/14651858.CD005196.pub3. PMID: 16856085 Updated.
-
Combination chemotherapy for high-risk gestational trophoblastic tumour.Cochrane Database Syst Rev. 2009 Apr 15;(2):CD005196. doi: 10.1002/14651858.CD005196.pub3. Cochrane Database Syst Rev. 2009. Update in: Cochrane Database Syst Rev. 2013 Jan 31;(1):CD005196. doi: 10.1002/14651858.CD005196.pub4. PMID: 19370618 Updated.
Cited by
-
Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour.Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD005196. doi: 10.1002/14651858.CD005196.pub4. Cochrane Database Syst Rev. 2013. PMID: 23440800 Free PMC article.
-
Gestational trophoblastic neoplasia: the management of relapsing patients and other recent advances.Curr Oncol Rep. 2004 Nov;6(6):476-82. doi: 10.1007/s11912-004-0079-1. Curr Oncol Rep. 2004. PMID: 15485618 Review.
-
The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia.J Cancer Res Clin Oncol. 2012 Jun;138(6):971-7. doi: 10.1007/s00432-012-1173-7. Epub 2012 Feb 23. J Cancer Res Clin Oncol. 2012. PMID: 22358303
-
A case of multi-agent drug resistant choriocarcinoma treated with Pembrolizumab.Gynecol Oncol Rep. 2020 Apr 23;32:100574. doi: 10.1016/j.gore.2020.100574. eCollection 2020 May. Gynecol Oncol Rep. 2020. PMID: 32395603 Free PMC article.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials